Lumasiran: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lumasiran. Educational only — not medical advice.
Labeled uses
OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] .
Source: FDA labeling via NIH DailyMed (set 16985a31…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.